Terms ending in 2036
Every in-force patent on Anavex Life Sciences Corp.'s record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,413,519 | CRYSTAL FORMS OF tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 10,966,952 | Crystal Forms of TETRAHYDRO-N,N-DIMETHYL-2,2-Diphenyl-3-Furanmethanamine Hydrochloride, Processes of Making Such Forms, and Their Pharmaceutical Compositions In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,617,734 | Enantiomers of A2-73, Analogues, and Sigma Agonist Activity In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,208,079 | Enantiomers of A2-73, Analogues, and Sigma Agonist Activity In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,383,526 | Optimized SIGMA-1 Agonist Method of Responder Selection and Treatment In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 12,759,986 | Crystal Forms of Tetrahydro-N, N-DIMETHYL-2, 2-Diphenyl-3-Furanmethanamine, Processes of Making Such Forms, and Their Pharmaceutical Compositions In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,661,405 | Crystal Forms of TETRAHYDRO-N,N-DIMETHYL-2,2-Diphenyl-3-Furanmethanamine Hydrochloride, Processes of Making Such Forms, and Their Pharmaceutical Compositions In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 10,195,192 | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 10,933,062 | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| US 11,896,590 | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof In force · High confidence | Anavex Life Sciences Corp. | In force | High confidence | |
| 1 more term end in 2036 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.